Abstract: Disclosed herein are Furin/PC inhibitors for inhibiting Furin and other Propprotein Convertases. Method of making the Furin/PC inhibitors, chemical and biological characterization of the Furin/PC inhibitors, and the use of the Furin/PC inhibitors to treat infectious diseases, cancers, and inflammatory/autoimmune disorders, are also disclosed.

Abstract: Compositions and methods for modulating miRNAs up-regulated or down-regulated in aged individuals and their downstream targets are disclosed. Methods of treating musculoskeletal disorders are also provided.

Abstract: A cobalt-based nano catalyst including a metal combination as a core and a porous material as a shell. The metal combination includes a first metal component Co, a second metal component selected from Ce, La, and Zr, and a third metal component selected from Pt, Ru, Rh, and Re. The catalyst includes between 10 and 35 wt. % of the first metal component, between 0.5 and 10 wt. % of the second metal component, between 0.02 and 2 wt. % of the third metal component, and a carrier. The carrier is a porous material such as nano silica or alumina. The carrier is in the shape of a spheroid, has a pore size of between 1 and 20 nm and a specific area of between 300 and 500 m2/g. The active component of the catalyst has a particle size of between 0.5 and 20 nm.

Abstract: Provided is a phosphor-functionalized nanoparticle that includes an inorganic nanoparticle core; surface polymer brushes that include a plurality of long-chain polymers bonded to the surface of the inorganic nanoparticle core, said long-chain polymers each having molecular weight greater than 500, and a plurality of short-chain polymers bonded to the surface of the inorganic nanoparticle core, said short-chain polymers each having molecular weight less than 0.5 times the average molecular weight of the long-chain polymers; and one or more organic phosphors bonded to at least one of the inorganic nanoparticle core and one or more of the plurality of short-chain polymers. Graft density of the short-chain polymers on the surface of the inorganic nanoparticle core (?SC) is greater than graft density of the long-chain polymers on the surface of the inorganic nanoparticle core (?LC). Also provided are polymer matrices, LED's, optical systems, lighting devices, and fixtures that include the inventive nanoparticle.

Abstract: The present invention provides the in-vitro use of at least one in-vivo-target antigen of Aspergillus fumigatus for selective activation, detection and/or analysis of Aspergillus fumigatus specific CD4+ T cells in a sample comprising cells, wherein said at least one in-vivo-target antigen reveals an immune reactivity characterized by i) the in vivo existence of antigen-specific T cells comprising more than 60% memory T cells and ii) said antigen-specific T cells further comprise T cells able to produce IFN-gamma upon stimulation at a frequency between 15% and 80% and/or IL17 upon stimulation at a frequency between 5% and 30%. Said at least one in-vivo-target antigen may be selected from the group consisting of antigens Scw4, Pst1, Shm2, GliT and TpiA or fragments thereof. Also provided are a method, a composition, and a kit thereof.

Abstract: Disclosed are a method and an apparatus for managing a resource in a small cell environment. The method for managing a resource in a small cell environment by a macro base station for controlling connection between user equipment (UE) and a gateway (GW), includes: configuring at least one packet path between the GW and the UE through a bearer of the macro base station; determining whether to add at least one small base station in the macro base station to the at least one packet path according to signal strength of the at least one small base station from the UE; and changing the at least one packet path using a bearer of a small base station based on the result.

Abstract: Provided herein is a method and apparatus for implementing a tunable light source, the method including performing a first calibration of obtaining a tuning curve representing changes of a wavelength as a function of a heater power up to a wavelength range where the external cavity type tunable light source is tunable; performing a second calibration of obtaining a detuning curve of the tunable wavelength range; and setting a wavelength by performing a wavelength locking.

Abstract: A power supply apparatus may include a transformer unit outputting a voltage transformed depending on an inductance ratio between a primary side and a secondary side, an inductance varying unit varying an inductance of the primary side depending on whether or not external input power is being input, and an output unit stabilizing the transformed voltage and outputting the stabilized voltage.

Abstract: Provided is a method and apparatus for discontinuously transmitting/receiving packets for low-power consumption of a terminal in a cellular system for packet transmission. The present research provides a method and apparatus that can perform a low-power consuming operation when a terminal is in active state in a cellular system. The method for discontinuously transmitting/receiving packet data to reduce power consumption of a terminal in a cellular system, including the steps of: a) establishing discontinuous reception/transmission (DRX/DTX) parameters including discontinuous DRX/DTX cycle information for terminals operating in a transmission suspension mode, which is a sub-state of an active state; and b) performing DRX/DTX based on the DRX/DTX parameters in the terminals operating in the transmission suspension mode.

Abstract: The present invention provides a phenyl C-glucoside derivative containing a deoxyglucose structure as represented by formula I, preparation method thereof, a pharmaceutical composition comprising the same, and uses thereof in the preparation of medicaments for treating diabetes, wherein substituents R1-R7 are as defined in the specification. The present invention also provides a method for synthesizing the phenyl C-glucoside derivative containing a deoxyglucose structure and an intermediate product. The method has advantages of being simple to manage and of low cost, which is suitable for large-scale industrial production. The present invention further provides a cocrystal of (1S)-1-[4-chloro-3-(4-ethoxybenzyl)phenyl]-1,6-dideoxy-D-glucose and L-proline, and preparation method and uses thereof.

Abstract: Provided are a carbon nanotube composite containing a carbon nanotube coated with a protein having a catechol group and a metal ion bound to the catechol group and a method for manufacturing the same. According to the present disclosure, a carbon nanotube composite which exhibits controllable dispersibility and degree of crosslinkage while retaining the intrinsic physical properties of the carbon nanotube may be prepared. Since the phase change and tendency of aggregation of the carbon nanotube composite can be controlled quickly and repeatedly depending on the change in external environment, the carbon nanotube composite may be useful in various industrial fields including medicine, environment, etc. as a self-healing material.

Abstract: A fast magnetic resonance imaging method and system, the method comprising: applying a periodic radio-frequency pulse train to drive the magnetization vector of an imaging volume into a steady state (102); acquiring a free induction decay (FID) signal and an echo signal alternately in a steady-state free precession sequence (104); conducting an FID signal imaging and a T2-weighted imaging (106). Alternate acquisition of the FID signal and the echo signal in the steady-state free precession sequence effectively increases the signal-to-noise ratio (SNR) of the acquired signals and reduces the sensitivity of the sequence to motions.

Abstract: Described herein are compounds of Formulae (I)-(II), and pharmaceutically acceptable salts, and pharmaceutical compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating or preventing proliferative diseases such as cancers (e.g., lung cancer, large bowel cancer, pancreas cancer, biliary tract cancer, or endometrial cancer), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases in a subject.

Abstract: The objective of the present invention is to provide a cleaning agent composition which can be used in the open air without any problems since the cleaning agent is environmentally friendly and which is effective for removing a low-molecular-weight and poorly-water-soluble cyclic silicone compound that causes a stain of a silicone sealing. The cleaning agent for washing out a silicone stain according to the present invention is characterized in comprising a cyclic lipopeptide biosurfactant, wherein the specific silicone stain compound such as D4 compound is the objective compound to be removed.

Abstract: Embodiments of branched polymer lubricant additives comprise a branched polymer and, when combined with a lubricant base at a concentration from 1 wt % to 50 wt %, provide (i) a viscosity index ?150, (ii) that is at least 10% less than a coefficient of friction of the lubricant base alone in contact with a component of a device during operation of the device at a temperature within a range of 20 to 100° C., or (iii) both (i) and (ii).

Abstract: Fungi, such as Aspergillus niger, having a dolichyl-P-Man:Man(5)GlcNAc(2)-PP-dolichyl mannosyltransferase (Alg3) gene genetic inactivation, increased expression of a loss of aflR expression A (LaeA), or both, are described. In some examples, such mutants have several phenotypes, including an increased production of citric acid relative to the parental strain. Methods of using the disclosed fungi to make citric acid are also described, as are compositions and kits including the disclosed fungi. Further described are Aspergillus terreus fungi overexpressing the LaeA gene and the use of such fungi for the production of itaconic acid.

Abstract: [Object] An object is to provide a brain activity measuring apparatus and a brain activity measuring method that can precisely ensure reproducibility of measurements for a plurality of measurements made separately for a number of times using functional magnetic resonance imaging. [Solution] In an MRI apparatus 10, a data processing unit 32 determines rigid transformation between an original tomographic image obtained in a past measurement and stored in a storage unit 36 and a pilot tomographic image obtained in a present imaging session such that mutual information between the original and pilot tomographic images is locally maximized; and based on a parameter of the determined rigid transformation, position and direction of a slice image of the tomographic image in the present imaging session are corrected.

Abstract: A resonance generating apparatus for testing blade fatigue with reduced side load includes a mounting portion comprising a saddle including a groove corresponding to an external surface of a blade, and an assembling portion positioned on an external side of the saddle and joined by tightening members so that the saddle presses against the blade, a resonance generator including an actuator to generate a linear movement, a coupler(s) to maintain phase of a blade motion the same as an actuator rod, and a linear guide to guide a direction of linear reciprocating motion of an actuator body, and weights mounted on opposite faces of the actuator body to move in association therewith, and varied in a lengthwise direction of the blade so a center of gravity of moving masses of the actuator body in linear reciprocation and the additional weights is positioned on an axis of the actuator rod.

Abstract: The present invention relates to the composition of a nanoparticle based on a magnesium salt, and methods of drug delivery using the nanoparticle. A preferred embodiment uses magnesium phosphate, with or without a shell to deliver aiRNA and/or siRNA. The nanoparticles of the present invention are also effective when administered orally.

Abstract: Small molecule inhibitors of Nrf2 and methods of their use are provided for treating or preventing a disease, disorder or condition associated with an Nrf2-regulated pathway. The compound can be administered as a single agent or can be administered to enhance the efficacy of a chemotherapeutic drug and/or radiation therapy.